Investigating the effects of T-5224 on HIV-1 activity in mice
Official title: PK/PD and Effect of T-5224 on HIV-1 Transcriptional Activity in an HIV-1-Mouse Model
Funded at University of Nebraska Medical Center · NIH-11164957 · Data updated 2026-11-12
This study is looking at how a new drug called T-5224 might help people with HIV by blocking the virus's ability to hide in the body, and it's being tested in mice to see how well it works and how safe it is for future treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | August 1, 2024 |
| Project end | October 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $849,004 |
| NIH project number | 75N93021D00006-0-759302400001-1 |
| Project ID | NIH-11164957 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who may benefit from new treatment options targeting HIV-1 transcriptional activity.
✕Less likely to help
Patients who are not infected with HIV or those who have already exhausted all available treatment options may not benefit from this research.
What this research studies
This research focuses on understanding how T-5224, an AP-1/c-Fos inhibitor, affects HIV-1 transcriptional activity using a mouse model that mimics human HIV infection. The study will assess the drug's tolerability, pharmacokinetics, and its ability to block latency in HIV-1. By conducting these experiments, researchers aim to gather critical data that could support the development of new therapeutic strategies for HIV treatment. The findings may lead to advancements in clinical trials and ultimately improve treatment options for patients living with HIV.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that more effectively manage or potentially eradicate HIV-1 in patients.
How similar studies have gone: Previous research has shown promise in targeting HIV-1 transcriptional activity, suggesting that this approach could lead to significant advancements in HIV treatment.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Gorantla, Santhi — University of Nebraska Medical Center
- Study coordinator: Gorantla, Santhi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.